Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Late last month, President Donald Trump issued letters to Lilly CEO David Ricks and to the CEOs of roughly a dozen other ...

Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for G protein ...

Trump administration demands lower U.S. prices on drugs like Mounjaro, forcing the pharmaceutical company to raise them in ...

Attorney General Ken Paxton filed a lawsuit this week against Eli Lilly for allegedly bribing Texas health care providers to ...

Texas is seeking more than $1 million from Eli Lilly in a lawsuit accusing the drugmaker of persuading physicians to prescribe its medications, including GLP-1s such as Mounjaro and Zepbound, through ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

More than 1 in 4 adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, the ...

By Nqobile Dludla and Siyanda Mthethwa JOHANNESBURG (Reuters) -Danish drugmaker Novo Nordisk introduced its weight-loss drug ...

Huge dividends from Denmark’s weight loss drug industry are result of high-tax and high-investment economy, says Nobel Prize winner Morten Meldal.